Back to results
US 6,143,744 AGranted
Sulfamide-metalloprotease inhibitors
AssigneesSyntex (U.S.A.) Inc., Agouron Pharmaceuticals, Inc.
InventorsChris Allen Broka, Jeffrey Allen Campbell, Arlindo Lucas Castelhano, Jian Jeffrey Chen, Robert Than Hendricks, Michael Joseph Melnick, Keith Adrian Murray Walker
Life of this patent
Estimating the term…
Abstract
This invention relates to sulfamides of formula (I) ##STR1## that are inhibitors of metalloproteases, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.
Claims46
A compound selected from the group of compounds represented by formula (I):
- ##STR41## wherein:
- R.sup.1 and R.sup.2 are independently selected from hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heteroaryl, heteroaralkyl, heterocyclo, heterocycloalkyl, heteroalkyl, or -(alkylene)-C(O)-X where X is alkyl, haloalkyl, alkoxy, haloalkyloxy, amino, monosubstituted amino, disubstituted amino, aryl, aralkyl, aryloxy, heteroaryloxy, hydroxy, aralkyloxy, heteroaralkyloxy, or heteroaryl;
- or R.sup.1 and R.sup.2 together with the carbon atom to which they are attached form a carbocycle or a heterocycle;
- R.sup.3 is hydrogen, alkyl, alkenyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaryl, heteroaralkyl, heteroaralkenyl, heterocycloalkyl, heteroalkyl, (diphenylmethyl)alkyl, or -(alkylene)-C(O)-X where X is alkyl, haloalkyl, alkoxy, haloalkyloxy, amino, monosubstituted amino, disubstituted amino, aryl, aralkyl, aryloxy, heteroaryloxy, hydroxy, aralkyloxy, heteroaralkyloxy, or heteroaryl;
- or R.sup.3 together with either R.sup.1 or R.sup.2 and the atoms to which they are attached forms a heterocycloamino group;
- R.sup.10 is --NR.sup.11 OR.sup.12 wherein:
- R.sup.11 and R.sup.12 are independently selected from hydrogen, alkyl, or aralkyl;
- R.sup.20 and R.sup.21 are independently selected from hydrogen, alkyl, heteroalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, aralkenyl, heteroaralkyl, or heteroaralkenyl;
- or R.sup.20 and R.sup.21 together with the nitrogen atom to which they are attached form a heterocycloamino group or an optionally substituted tetrahydropyridine or hexahydroazepine ring;
- or either of R.sup.20 or R.sup.21 together with R.sup.3 forms an alkylene group;
- and
- their pharmaceutically acceptable salts, prodrugs, individual isomers, and mixtures of isomers, provided that R.sup.20 and R.sup.21 together with the nitrogen atom to which they are attached do not form a morpholino ring either:
- (i) when R.sup.1 and R.sup.3 are hydrogen and R.sup.2 is aralkyl;
- or
- (ii) when R.sup.1 and R.sup.3 together with the atoms to which they are attached form a tetrahydroisoquinoline ring and R.sup.2 is hydrogen.
12 more elements
Dependencies are inferred from the claim text.